FDA clears IND application for CAR-natural killer cell therapy to treat B-cell malignancies
Click Here to Manage Email Alerts
The FDA cleared an investigational new drug application for NKX019, a chimeric antigen receptor-natural killer cell therapy for patients with relapsed or refractory B-cell malignancies, according to the agent’s manufacturer.
NKX019 (Nkarta) is an allogeneic, gene-edited CAR-natural killer (NK) cell therapy that targets the CD19 protein on the surface of cancer cells.
The therapy — derived from the peripheral blood of healthy donors — includes Nkarta’s propriety membrane-bound interleukin-15 activation cytokine to promote NK cell growth and enhanced CAR-NK cell persistence.
The IND clearance will allow Nkarta to begin enrollment of a phase 1 clinical trial that will evaluate NKX019 for patients with relapsed or refractory B-cell malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia. The study is scheduled to begin in the second half of this year.
“Academic studies have highlighted the ability of donor-derived NK cells, when collected from healthy donors, to effectively target and kill cancer cells without some of the safety risks commonly associated with T-cell therapies,” Kanya Rajangam, MD, PhD, chief medical officer of Nkarta, said in a company-issued press release. “We look forward to evaluating NKX019 in our trial as a planned multidose, multicycle treatment regimen to determine its potential for enhanced antitumor activity with a beneficial safety profile.”
Nkarta is conducting a multicenter phase 1 trial of NKX101, an allogeneic, gene-edited CAR-NK cell therapy that targets NKG2D ligands expressed by cancer cells. That trial includes adults with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Read more about
Click Here to Manage Email Alerts